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Short Communication
MMP-2 and MMP-9 in normal mucosa are independently
associated with outcome of colorectal cancer patients
AMJ Langers*,1, HW Verspaget1, LJAC Hawinkels1,2, FJGM Kubben1, W van Duijn1, JJ van der Reijden1,
JCH Hardwick1, DW Hommes1 and CFM Sier1,3
1Department of Gastroenterology-Hepatology, Leiden University Medical Centre, PO Box 9600, 2300RC, Leiden, The Netherlands; 2Department of
Molecular Cell Biology, Leiden University Medical Centre, Leiden, The Netherlands; 3Department of Surgery, Leiden University Medical Centre, Leiden,
The Netherlands
BACKGROUND: Upregulation of the matrix metalloproteinases MMP-2 and MMP-9 in various cancers has been associated with worse
survival of the patients.
METHODS: We assessed MMP-2 and MMP-9 levels in normal colorectal mucosa from colorectal cancer patients in relation to the
course of the disease.
RESULTS: A high protein expression of MMP-2 as well as MMP-9 in normal mucosa was found to be correlated with worse 5-year
survival. The combination of both parameters was an even stronger prognostic factor. These protein levels were found not to be
related to the corresponding single nucleotide polymorphisms of MMP-2 (1306C4T) and MMP-9 (1562C4T). Multivariate
analyses indicated that the MMP-2 and MMP-9 levels in normal mucosa are prognostic for survival, independent of TNM classification.
CONCLUSION: MMP-2 and MMP-9 levels in normal mucosa are indicative of the course of disease in colorectal cancer patients.
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The gelatinases MMP-2 and MMP-9 are implicated in the process
of colorectal cancer progression, angiogenesis and metastasis
(Zucker and Vacirca, 2004). We previously reported that MMP-2
genotype and high levels of tumour MMP-2 are associated with a
poor survival in colorectal cancer patients. For MMP-9, we found a
bivalent correlation between MMP-9 expression and survival, that
is, patients with either very low or very high MMP-9 tumour
protein levels have worse survival compared with patients with
intermediate MMP-9 expression (Langers et al, 2008). In contrast,
little is known about the impact of MMP expression in normal
mucosa of cancer patients. We hypothesised that the expression of
MMP-2 and MMP-9 in normal mucosa of colorectal cancer
patients could be relevant as well to the outcome in colorectal
cancer. The aim of the present study was to evaluate the relation of
the genotype and phenotype of MMP-2 and MMP-9 in normal
appearing mucosa with outcome of patients with colorectal cancer.
MATERIALS AND METHODS
Patients and study design
Tumour tissue and normal appearing mucosa at a distance of
5–10 cm from the tumour was collected from 198 consecutive
patients (85 female and 113 male) who underwent surgery for
colorectal cancer between 1983 and 1991 at Leiden University
Medical Centre. All patients from whom tissue was obtained and
data collection was complete were included in this retrospective
study of prospectively collected tissues. None of the patients
received (neo) adjuvant chemo- and/or radiotherapy. The
surgical procedure consisted of removal of the tumour with
en bloc resection of the lymph nodes. Tissue samples were snap
frozen and stored at 70 1C until use. Macroscopic and micro-
scopic parameters were obtained from the pathological reports,
including TNM classification. Clinical data and follow-up informa-
tion was available for a period of at least 5 years. The primary end
point was survival at 5 years after surgery. Patient characteristics
were as follows: 67% of patients was 465 years of age, TNM
classification was stage 1 in 17%, stage 2 in 40%, stage 3 in 29%
and stage 4 in 14% of the patients. The tumour was localised in the
right hemicolon in 36% of the patients, 42% had left-sided cancer
and in 22% the tumour was localised in the rectum. In 42% of the
patients, the tumour was smaller than 5 cm in diameter and in 23%
there was a mucinous component in the histology. Histological
differentiation grade was poor in 13% of the patients, moderate in
70% and good in 17% of the patients. Parameters considered for
inclusion in the multivariate analysis were: MMP-2 and MMP-9 in
normal mucosa, tumour stage, age and gender. The study was
performed according to the instructions and guidelines of the
LUMC Medical Ethics Committee and in accordance with the
Helsinki Declaration.
Tissue preparation and protein concentration
Tissue homogenates were prepared in 0.1 M Tris-HCl (pH 7.5) with
0.1% (v/v) Tween 80 extraction buffer as previously described
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(Mulder et al, 1990). The protein concentration was determined
(Lowry et al, 1951).
Determination of MMP-2 and MMP-9 in tissue
homogenates
Levels of MMP-2 and MMP-9 were determined in homogenates by
previously described ELISAs (Gao et al, 2005). In short, polyclonal
anti-MMP-2 or monoclonal anti-MMP-9 antibodies were used as
catching antibody and appropriately diluted samples were
incubated overnight at 4 1C. Immune-detection was performed
using polyclonal rabbit anti-MMP-2 followed by biotin-labelled
goat anti-rabbit-IgG for MMP-2 and biotin-labelled polyclonal
anti-MMP-9 antibodies for MMP-9. After incubation with avidin-
peroxidase, the chromogenic substrate 3,30,5,50-tetramethyl benzi-
dine was added in the presence of hydrogen peroxide. The reaction
was stopped with H2S04 and the absorption was measured at
450 nm. The amount of MMP was calculated from parallel-
incubated standard curves of MMP-2 or MMP-9 and expressed
in ng per mg protein of the homogenate.
Single nucleotide polymorphism (SNP) analysis
Genomic DNA was isolated from the tissues using the salting out
method (Miller et al, 1988). The SNP analysis for MMP-21306C4T
and MMP-91562C4T was performed by restriction fragment length
polymorphism—polymerase chain reaction as described earlier
(Kubben et al, 2006; Meijer et al, 2006) or by tetra primer ARMS
PCR, involving four oligonucleotide primers but no restriction
enzymes (Meijer et al, 2006). Genotype frequencies for MMP-2-
1306C4T were CC: n¼ 108: CT: n¼ 79 and TT: n¼ 11, and for
MMP-9-1562C4T CC: n¼ 139; CT: n¼ 50 and TT: n¼ 9.
Statistical analyses
Statistical analyses were performed using SPSS 17.0. Statistical
Package (SPSS Inc., Chicago, IL, USA). Expression differences
between groups were calculated using the Mann–Whitney U-test.
Log Rank statistics (LR) was used for optimal cut point analysis
(Hothorn, 1994). Hardy–Weinberg analysis was performed using
w2 or Fisher’s exact test to examine differences in the distribution
of alleles and genotypes. Multivariate analyses were performed by
adding every single MMP-related parameter to the dichotomised,
prognosis-associated clinico-pathological parameters gender, age
and TNM stage. Correlations between parameters were calculated
according to Pearson’s correlation test. P-values smaller than 0.05
were considered significant.
RESULTS
The median protein level of MMP-2 and MMP-9 in the normal
mucosa of the 198 colorectal cancer patients was 4.8 ngmg1
protein (range, 0–30.5) for MMP-2 and 3.2 ngmg1 protein
(range, 0.2–164.7) for MMP-9. As expected, MMP expression in
normal mucosa was lower than in carcinoma tissue: 2-fold lower
for MMP-2 (Figure 1A, median carcinomas 10.6 ngmg1 protein)
and 12-fold lower for MMP-9 (median carcinomas 36.7 ngmg1
protein). The MMP-2 levels in the normal mucosa correlated
significantly with the levels in cancer tissue (R¼ 0.489, Pp0.0001
for all genotypes together; results per genotype are shown in
Figure 1A), whereas the MMP-9 levels did not (R¼ 0.034,
P¼ 0.637). The highest levels of MMP-2 and MMP-9 were found
in the mucosa from TNM stage IV patients, but the differences
with and between the other stages were not statistically significant
(data not shown). Optimal cutoff point analyses of mucosal
MMP-2 and MMP-9 protein levels divided the patients in
subgroups with significant differences in survival. High levels of
MMP-2 (cutoff 8.7 ngmg1 protein, LR 12.82, Po0.001, Figure 1B)
or MMP-9 (cutoff 1.6 ngmg1 protein, LR 10.41, P¼ 0.001,
Figure 1C) were associated with poorer 5-year survival. The
combination of both mucosal MMP-based parameters appeared as
a highly significant discriminator (LR 20.30, Po0.0001) for
subdivision of patients into good, intermediate and poor survivors
as shown in Figure 1D.
The genotypes of the MMP-2-1306C4T and MMP-9-1562C4T
polymorphism were distributed according to the Hardy–Weinberg
equilibrium (MMP-2 w2¼ 0.49, P¼ 0.48; MMP-9 w2¼ 2.5, P¼ 0.11)
and there was no association between the different genotypes and the
levels of MMP-2 and -9 in normal mucosa (data not shown).
Univariate Cox analysis confirmed the association of the tissue
levels of MMP-2 and MMP-9 with survival (Table 1). Multivariate
Cox analysis, including the clinical parameters gender, age
and TNM stage of the tumour, showed both mucosal MMPs to
be independent indicators of prognosis (hazard ratios 41.7,
P¼ 0.009). A separate multivariate analysis of the MMP-2/MMP-9
combination indicated a highly significant hazard ratio for patients
with high mucosal levels of both MMPs.
DISCUSSION
In the present study, we found high protein levels of MMP-2 and
MMP-9 in mucosa adjacent to colorectal cancer tissue to be
indicative for the course of disease, that is, independently
associated with a worse survival of the patients. Mucosa
immediately adjacent to colon cancer (within 2 cm) shares
histochemical, ultrastructural and biological features with the
corresponding tumour and is referred to as transitional mucosa
(Boland and Kim, 1987). But even at longer distances from the
tumour, enhanced calcium levels and increased numbers of
aberrant crypts are detected, indicating differences with mucosa
from healthy controls (Edelstein et al, 1991; Pretlow et al, 1991).
Some of these changes are clearly related to changes in the
endothelium. ‘Normal’ mucosa adjacent to larger, more invasive
tumours showed enhanced microvessel densities compared with
less invasive tumours, which was associated with increased levels
of the angiogenic factors vascular endothelial growth factor
(VEGF), interleukin-8 and factor VIII-related antigen (Fox et al,
1998). These differences in the normal mucosa were not related to
the survival of the patients. We have previously shown that low
levels of the endothelium-derived serine proteinase tissue-type
plasminogen activator (tPA) in normal appearing mucosa of
colorectal and gastric cancer patients is also associated with poor
prognosis (Ganesh et al, 1994; Ganesh et al, 1997). The correlation
of high protein levels of MMP-2 and MMP-9 in mucosa adjacent to
colorectal cancer tissue with worse survival, as we found, is
probably also more, but not exclusively, related to endothelial cells
in combination with epithelial cells and/or leukocytes. Previously
we showed that MMP-2 in the intestinal mucosa of colorectal
cancer patients is predominantly expressed in the submucosal
extracellular matrix and MMP-9 in the mucosal macrophages and
neutrophils (Gao et al, 2005). We hypothesised previously that the
poor prognosis found for patients with very low tumour MMP-9
levels is possibly due to the lack of infiltrating leukocytes, which
may possess anti-cancer effects (Langers et al, 2008). Diffuse
staining of a subset of microvessels in tumour-adjacent mucosa of
the oesophagus by CD105/endoglin, a neovascularisation marker,
has been found to correlate statistically with worse overall survival
of the patients (Bellone et al, 2007). Interestingly, we previously
observed that MMP-9 is involved in the VEGF-mediated neo-
angiogenesis in colorectal cancer and that MMP-mediated
endoglin mobilisation is involved in the regulation of the
angiogenic potential of endothelial cells in colorectal cancer
(Hawinkels et al, 2008; Hawinkels et al, 2010). Angiogenesis in
the adjacent mucosa might very well enhance the development of
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multi-focal tumours or regional metastasis, which could explain
the correlation with survival.
We have previously shown that there is no association between
SNPs of MMP-2 and MMP-9 and the amount of corresponding
protein in colorectal carcinomas (Langers et al, 2008). But in a
tumour environment, the final concentration of MMP-2 and -9
would depend on many different cell types, mechanisms and
interactions. Therefore, one could speculate that an association
Table 1 Univariate and multivariate Cox proportional hazard analysis for 5-year survival in normal appearing mucosa from 198 patients with colorectal
cancer
Univariate Multivariate
Parameter N HR CI 95% P HR CI 95% P
Gender F-M 85–113 1.195 0.830–1.719 0.339 1.164 0.808–1.677 0.414
Age o65 years4 66–132 1.861 1.230–2.815 0.003 2.003 1.322–3.035 0.005
TNM I+II-III+IV 113–85 2.972 2.056–4.297 0.000 3.083 2.129–4.465 0.000
MMP mucosal
MMP-2 o8.74 154–44 1.898 1.273–2.828 0.002 1.718 1.145–2.578 0.009
MMP-9 o1.64 48–150 2.323 1.421–3.796 0.001 1.948 1.184–3.204 0.009
MMP-2/MMP-9 combinationa o,o 46 Ref — — Ref — —
Rest 110 1.839 1.105–3.063 0.019 1.582 0.946–2.645 0.080
4,4 42 3.310 1.882–5.821 0.000 2.638 1.486–4.683 0.001
Abbreviations: CI¼ confidence interval; F-M¼ female-male; HR¼ hazard ratio; MMP¼matrix metalloproteinase; Ref¼ reference group. aIn the multivariate analysis for the
MMP-2/MMP-9 combination, the separate variables MMP-2 and MMP-9 protein were not included. o,o¼MMP-2o8.7 ngmg1 protein and MMP-9o1.6 ngmg1 protein;
4,4¼MMP-248.7 ngmg1 protein and MMP-941.6 ngmg1 protein. Multivariate analysis was performed by adding every single MMP-related parameter to the
dichotomised, prognosis-associated clinico-pathological parameters gender, age and TNM stage. Statistically significant values are given in bold.
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Figure 1 (A) Correlation between the tissue MMP-2 levels (in ngmg1 protein) in normal mucosa and corresponding carcinoma tissue obtained from
198 colorectal cancer patients. The left panel shows the correlation in patients with a CC genotype, the middle panel in patients with a CT genotype and the
right panel shows the correlation in patients with a TT genotype of the -1306CT polymorphism of MMP-2. Indicated are the Pearson’s correlation
coefficients for MMP-2 levels in normal mucosa and corresponding tumour and their corresponding P-value. (B and C) Optimal cutoff point analysis and
corresponding Kaplan–Meier 5-year survival curves for dichotomised (high/low) levels of MMP-2 (B) and MMP-9 (C) in normal mucosa. The optimal cutoff
points are indicated with arrows. In the survival curves, the total number of patients and the deceased patients (w) are indicated per subgroup. (D) Kaplan–
Meier 5-year survival curves for combination of MMP-2 and MMP-9 in normal mucosa (both MMP-2 and MMP-9 high (lower, thick line), both MMP-2 and
MMP-9 low (upper, dashed line), either MMP-2 high and MMP-9 low or MMP-2 low and MMP-9 high (intermediate, thin line); for cutoff points see B and C).
The total number of patients and the deceased patients (w) are indicated per subgroup.
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between the SNP and the amount of MMP protein in normal
mucosa would be more likely. T allele carriers of the
MMP-21306C4T polymorphism have lower promoter activity
due to disruption of an Sp-1-binding site (Price et al, 2001), while
T allele carriers of the MMP-91562C4T polymorphism have
increased transcriptional activity due to preferential binding of a
transcription suppressor protein to the C allele (Zhang et al, 1999).
Although normal mucosa MMP-2 levels correlated significantly
with their corresponding tumour levels, this was not restricted to
or within a specific genotype. The tissue levels of MMP-9, either
from normal mucosa or tumour, did not correlate and were also
independent from the genotypic background. In a recent review
about SNPs of MMPs and gastrointestinal cancer, we already
emphasised that due to the complicated regulatory processes after
transcription, SNPs are not very strong effectors of overall
synthesis/presence of the corresponding MMP in vivo (Langers
et al, 2011).
In conclusion, this study shows that increased MMP-2
and MMP-9 protein expression in normal mucosa at
some distance of colorectal tumours is strongly related to the
course of disease, that is, independently associated with a poor
prognosis of colorectal cancer patients. The difference in mucosal
expression of the gelatinases cannot be attributed to genotypic
variations.
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